Clinical trial
4-Methylumbelliferone as a Treatment for Chronic HBV/HCV
NCT00225537 · MTmedical Institute of Health, Other · Unknown status
Key facts
| NCT number | NCT00225537 |
|---|---|
| Title | 4-Methylumbelliferone as a Treatment for Chronic HBV/HCV |
| Official title | Evaluation of 4-Methylumbelliferone for Treatment of Chronic Hepatitis B (HBV) and Chronic Hepatitis C (HCV) |
| Lead sponsor | MTmedical Institute of Health, Other |
| Collaborators | The University of Texas Health Science Center at San Antonio BioMonde Preparations Limited |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis C, Chronic Hepatitis B |
| Intervention type | Drug |
| Interventions | 4-Methylumbelliferone (Heparvit®) |
| Enrollment | 160 |
| Start date | Sep 1, 2005 |
| Completion | Aug 1, 2007 |
| First posted | Sep 23, 2005 |
| Last update posted | Sep 11, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: